VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ The treating physician has chosen Ventavis as a   │ The treating physician has chosen Ventavis as a   │     100 │
│ suitable long-term treatment for the patient      │ suitable long-term treatment for the patient      │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patient with primary pulmonary hypertension (i.e. │ Patient with primary pulmonary hypertension (i.e. │     100 │
│ Idiopathic Pulmonary Arterial Hypertension or     │ Idiopathic Pulmonary Arterial Hypertension or     │         │
│ Familial Pulmonary Arterial Hypertension) and     │ Familial Pulmonary Arterial Hypertension) and     │         │
│ classified as NYHA functional class III (NYHA =   │ classified as NYHA functional class III (NYHA =   │         │
│ New York Heart Association)                       │ New York Heart Association)                       │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ No prior treatment with Ventavis or other active  │ No prior treatment with Ventavis or other active  │     100 │
│ treatments for primary pulmonary hypertension     │ treatments for primary pulmonary hypertension     │         │
│ within 6 weeks of date of study inclusion (unless │ within 6 weeks of date of study inclusion (unless │         │
│ otherwise advised by Bayer Schering Pharma)       │ otherwise advised by Bayer Schering Pharma)       │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Any condition that prevents participation in the  │ Any condition that prevents participation in the  │     100 │
│ study, including pregnancy and other              │ study, including pregnancy and other              │         │
│ contraindications for Ventavis treatment (as      │ contraindications for Ventavis treatment (as      │         │
│ listed in the current Ventavis Summary of Product │ listed in the current Ventavis Summary of Product │         │
│ Characteristics and patient package insert)       │ Characteristics and patient package insert)       │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                   │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ The treating physician has chosen Ventavis as a │      29 │
│                                   │ suitable long-term treatment for the patient    │         │
╘═══════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 85.8
OverAll Ratio: 91.9
